BenjaminBakallMDPhD

Ophthalmology • Phoenix, AZ

Retinal Disease

Medical retina/Inherited retinal dystrophies

Join to view full profile

Dr. Bakall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bakall's full profile

Already have an account?

Office
1750 E Glendale Ave
Phoenix, AZ 85020
Phone+1 602-242-4928

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Medical Retina, 2011 - 2013
University of Arizona College of Medicine-TucsonResidency, Ophthalmology, 2008 - 2011
University of Arizona College of Medicine2007 - 2008
University of Arizona College of MedicinePost-Doctoral Fellowship, 2005 - 2007
Uppsala University Faculty of MedicineClass of 2005
Uppsala UniversityPhD, 2003
University of Iowa Hospitals and ClinicsResidency, Ophthalmology

Certifications & Licensure

AZ State Medical License 2013 - 2026
AZ State Medical License 2007 - 2024
IA State Medical License 2011 - 2018
OH State Medical License 2010 - 2011
American Board of Ophthalmology Ophthalmology

Publications & Presentations

PubMed

158 citations
Expression of bestrophin-1, the product of the VMD2 gene, modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells
Rita Rosenthal, Benjamin Bakall, Tyson R. Kinnick, Neal S. Peachey, SÃ¶nke Wimmers
FASEB Journal. 2006-01-01
183 citations
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Benjamin Bakall, James C. Folk, H. Culver Boldt, Elliott H. Sohn, Edwin M. Stone
American Journal of Ophthalmology. 2013-07-01
135 citations
Non-exomic and synonymous variants in ABCA4 are an important cause of Stargardt disease
Terry A. Braun, Robert F. Mullins, Alex H. Wagner, Jeaneen L. Andorf, Rebecca M. Johnston
Human Molecular Genetics. 2013-12-20

Press Mentions

Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GADecember 15th, 2023
Ocugen, Inc. Announces the First Patient Dosed in Phase 3June 21st, 2024
Ocugen Doses First Patient with Gene Therapy for Retinitis Pigmentosa in Phase 3 TrialJuly 7th, 2024